Results 111 to 120 of about 838,980 (200)

Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report. [PDF]

Gynecol Oncol Rep
Thomas M, Devouassoux-Shisheboran M, Lopez J, Descargues P, Gertych W, Caraivan I, You B, Péron J.   +7 more
europepmc   +1 more source

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma. [PDF]

Exp Hematol Oncol
Brooks C, Mader L, Kennedy K, Naing PT, Sengsayadeth S, Dholaria B, Kassim A, Profitt S, Baljevic M.   +8 more
europepmc   +1 more source

Pregnancy, Postpartum, and Parenting Engagement Resource Center: A national resource for researchers, community organizations, and parents with substance use disorders. [PDF]

Drug Alcohol Depend Rep
Cioffi CC, Casper M, Leve LD, DeGarmo DS.   +3 more
europepmc   +1 more source

Medicaid payment rates for substance use disorder treatment-design, data, and lack of transparency. [PDF]

Health Aff Sch
Tormohlen KN, Crable EL, McGinty EE.
europepmc   +1 more source

On dirait le Sud

, 2007
Landy, Frédéric, Gervais-Lambony, Philippe   +1 more
openaire   +3 more sources

Is Morning Exposure Therapy More Successful? Pilot Data on Exposure Process Indicators and Diurnal Cortisol in Obsessive-Compulsive Disorder or Agoraphobia. [PDF]

J Clin Med
Kellner M, Santai Mareljic M, Yassouridis A.   +2 more
europepmc   +1 more source

Beyond fax: provider perspectives on data sharing in substance use disorder care. [PDF]

JAMIA Open
Kaiser M, Wei M, Nookala SP, Cooper R, Ariosto D, Adams C, Grando A, Sadeghi M, Murcko AC.   +8 more
europepmc   +1 more source

Service user and healthcare-worker perspectives on Substance Use Disorder treatment journeys, relapse, and recovery in Sub-Saharan Africa: Evidence from Uganda. [PDF]

PLOS Glob Public Health
Biribawa C, Vanderplasschen W, Mutyoba JN, Mutamba BB, Kalani K, Oyet D, Kalema D, Tumwesigye NM, Simpson V.   +8 more
europepmc   +1 more source